Biotech RadarJobs updated

COMPANY

Centrexion Therapeutics

HQ: Boston, MA source · centrexion.com ↗ · New England

Clinical Phase 1

Centrexion Therapeutics recognizes the needs of the those living with chronic pain and autoimmune disease and aims to develop new, safe and effective therapies that overcome the limitations and challenges of current treatments. From company website Source · Oct 13, 2026

Keywords: therapeutics Knee Osteoarthritis Nociceptive Pain Morton's Neuroma Lower Back Pain Painful Diabetic Neuropathy Osteoarthritis Painful Intermetatarsal Neuroma (Morton's Neuroma) Osteoarthritis of the Knee Acute-onset Herpes Zoster Pain CNTX-4975-05 CNTX-4975-05 (trans-capsaicin) CNTX-4975 CNTX-3001 CNTX-6016 CNTX-6970 CTNX-4975

Profile checked Oct 10, 2026

15Trials (company is sponsor)3NIH grants

Timeline

  1. Trial start Phase 1: Safety and PK of Intrathecal CNTX-3001 for Intractable Chronic Low Back Pain source ↗
  2. Trial start Phase 1: Safety, Tolerability & Pharmacokinetics Study of CNTX-6016 in Healthy Subjects and Subjects With PDN source ↗
  3. Trial start Phase 1: A Study to Evaluate the Safety and Pharmacokinetics of CNTX-6016 in Healthy Subjects source ↗
  4. Trial start Phase 3: An Open-label, 8-week Safety, Efficacy, and Assessment of Cooling Methods for Administration of CNTX-4975-05 for Knee OA source ↗
  5. Trial start Phase 3: A Clinical Study to Test Efficacy and Safety of Repeat Doses of CNTX-4975-05 in Patients With Osteoarthritis Knee Pain source ↗
  6. Trial start Phase 1: A Study to Compare Levels of Capsaicin After Intra-Articular Injection and Topical Application in Patients With Painful Knee Osteoarthritis source ↗
  7. Trial start Phase 1: The Effect of Injection Site Cooling on Pain Experienced After the Administration of CNTX-4975-05 Into the Knee source ↗
  8. Trial start 3: A Phase 3 Efficacy and Safety Study of Intra-articular CNTX-4975-05 (Capsaicin) vs Placebo in Subjects With OA Knee Pain source ↗
  9. Trial start Phase 1: A Placebo-Controlled, Two-Part Study, Oral Dose to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of CNTX-6970 in Healthy Subjects source ↗
  10. Trial start Phase 2: A Study to Evaluate the Safety and Efficacy of CNTX-4975 in Subjects With Painful Intermetatarsal Neuroma (Morton's Neuroma) source ↗
  11. Trial start Phase 2: Study to Evaluate the Safety and Efficacy of CNTX-4975 in Subjects With Chronic, Moderate to Severe Osteoarthritis Knee Pain source ↗
  12. Trial start Phase 1: Study to Evaluate the Safety and Pharmacokinetics of Topically Applied 40% Lidocaine Gel Compared With Placebo in Subjects With Acute Herpes Zoster (Shingles) Pain source ↗
  13. Trial start Phase 2: A Study to Evaluate the Efficacy and Safety of CNTX-4975 in Subjects With Painful Intermetatarsal Neuroma (Morton's Neuroma) source ↗
  14. Trial start Phase 1: Study to Evaluate the Safety and Tolerability of CNTX-4975 in Subjects With Painful Intermetatarsal Neuroma (Morton's Neuroma) source ↗
  15. Trial start Phase 2: Safety and Tolerability of 4975 in the Treatment of Moderate to Severe Knee Pain Due to Osteoarthritis (OA) source ↗

Upcoming milestones

Estimated primary completion per ClinicalTrials.gov. Dates move.

Clinical trials (lead sponsor) 15

RecordTitlePhaseStatusStartPrimary completion
NCT07122453Safety and PK of Intrathecal CNTX-3001 for Intractable Chronic Low Back PainPhase 1Recruiting2026-032027-01 (estimated)
NCT04857957Safety, Tolerability & Pharmacokinetics Study of CNTX-6016 in Healthy Subjects and Subjects With PDNPhase 1CompletedApr 14, 2021Aug 30, 2023 (actual)
NCT03429049A Phase 3 Efficacy and Safety Study of Intra-articular CNTX-4975-05 (Capsaicin) vs Placebo in Subjects With OA Knee Pain3CompletedJan 24, 2018Nov 22, 2019 (actual)
NCT03660943A Clinical Study to Test Efficacy and Safety of Repeat Doses of CNTX-4975-05 in Patients With Osteoarthritis Knee PainPhase 3CompletedSep 9, 2018Jun 11, 2020 (actual)
NCT03661996An Open-label, 8-week Safety, Efficacy, and Assessment of Cooling Methods for Administration of CNTX-4975-05 for Knee OAPhase 3CompletedSep 18, 2018Oct 22, 2019 (actual)
NCT04154501A Study to Evaluate the Safety and Pharmacokinetics of CNTX-6016 in Healthy SubjectsPhase 1CompletedDec 4, 2018Aug 21, 2019 (actual)
NCT03787004A Placebo-Controlled, Two-Part Study, Oral Dose to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of CNTX-6970 in Healthy SubjectsPhase 1CompletedAug 14, 2017Aug 19, 2018 (actual)
NCT03472677The Effect of Injection Site Cooling on Pain Experienced After the Administration of CNTX-4975-05 Into the KneePhase 1CompletedMar 21, 2018Jul 27, 2018 (actual)
NCT03576508A Study to Compare Levels of Capsaicin After Intra-Articular Injection and Topical Application in Patients With Painful Knee OsteoarthritisPhase 1CompletedJun 25, 2018Sep 6, 2018 (actual)
NCT02678793A Study to Evaluate the Safety and Efficacy of CNTX-4975 in Subjects With Painful Intermetatarsal Neuroma (Morton's Neuroma)Phase 2Completed2015-122016-12 (actual)
NCT02558439Study to Evaluate the Safety and Efficacy of CNTX-4975 in Subjects With Chronic, Moderate to Severe Osteoarthritis Knee PainPhase 2Completed2015-082016-10 (actual)
NCT02283957A Study to Evaluate the Efficacy and Safety of CNTX-4975 in Subjects With Painful Intermetatarsal Neuroma (Morton's Neuroma)Phase 2Completed2014-102015-08 (actual)
NCT00667654Safety and Tolerability of 4975 in the Treatment of Moderate to Severe Knee Pain Due to Osteoarthritis (OA)Phase 2Completed2007-082008-06 (actual)
NCT02679339Study to Evaluate the Safety and Pharmacokinetics of Topically Applied 40% Lidocaine Gel Compared With Placebo in Subjects With Acute Herpes Zoster (Shingles) PainPhase 1Terminated2015-012015-08 (actual)
NCT02550756Study to Evaluate the Safety and Tolerability of CNTX-4975 in Subjects With Painful Intermetatarsal Neuroma (Morton's Neuroma)Phase 1Completed2014-022014-11 (actual)

NIH awards 3

Annual award amounts. Total $8.7M.

Connect

Contact page

Feedback